Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients
Iliès Benotmane, Aurélie Velay, Gabriela Gautier-Vargas, Jérôme Olagne, Augustin Obrecht, Noëlle Cognard, Françoise Heibel, Laura Braun-Parvez, Nicolas Keller, Jonas Martzloff, Peggy Perrin, Romain Pszczolinski, Bruno Moulin, Samira Fafi‐Kremer, Olivier Thaunat, Sophie Caillard
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)DosingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care unitNeutralizing antibodyAcute respiratory distressAcute kidney injuryAntibodyInternal medicineAnesthesiaImmunologyLungInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAntibiotics Pharmacokinetics and Efficacy